CV Thera initiates CVT-3619 trial

USA-based CV Therapeutics has enrolled the first patient in a Phase I trial of CVT-3619, a partial A1 adenosine receptor agonist and novel oral compound for potential treatment of cardiometabolic diseases.

The trial will assess the safety and pharmacokinetic profile of CVT-3619 in healthy volunteers. The program will provide early data on the compound's potential effects on circulating levels of free fatty acids, which are associated with high blood lipid levels, insulin resistance and other cardiometabolic risk factors. The compound binds to the adenosine A1 receptor on fat cells, called adipocytes, potentially leading to a reduction in the breakdown in fats, also known as lipolysis, and a lowering of free fatty acids in preclinical models. Preclinical studies have also shown that the agent improves insulin sensitivity, lowers elevated triglycerides and may reduce very-low-density lipoproteins and potentially raise high-density lipoproteins.